Nasdaq · Biotech stocks database

BLSM — BlossomHill Therapeutics Inc.

BLSM (BlossomHill Therapeutics Inc.) stock: $25.74, $778.7M market cap, $116.0M cash, $662.7M EV. Next expected readout: Jan-29. Lead program: BH-30643 (NSCLC (Advanced Non-small Cell Lung Cancer)), Phase 1/2. Data from Fully Diluted's biotech stocks database.

Share price

$25.74

Market cap

$778.7M

Cash

$116.0M

Enterprise value

$662.7M

Balance sheet

Cash	$116.0M
Debt	$0.0M
Net cash	$116.0M
Enterprise value	$662.7M
Basic shares	21.3M shares
Fully diluted shares	Not disclosed
Fully diluted market cap	Not disclosed
Cash per share	$5.45

Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.

Price history

Loading BLSM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 14 - Apr 25	BH-30643	Phase 1/2	NSCLC (Advanced Non-small Cell Lung Cancer)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	BH-30643
Lead indication	NSCLC (Advanced Non-small Cell Lung Cancer)
Lead phase	Phase 1/2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06706076	Phase 1/2	Recruiting	Sponsor	BlossomHill Therapeutics	—	NSCLC (Advanced Non-small Cell Lung Cancer)	—
NCT06501196	Phase 1	Recruiting	Sponsor	BlossomHill Therapeutics	—	Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for BlossomHill Therapeutics on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego

BLSM — BlossomHill Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline

Active clinical trials